EverSource Wealth Advisors LLC acquired a new stake in AstraZeneca PLC (OTCMKTS:AZNCF – Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 7,954 shares of the company’s stock, valued at approximately $1,396,000.
A number of other large investors have also made changes to their positions in the company. Burling Wealth Partners LLC bought a new stake in shares of AstraZeneca in the 4th quarter valued at $4,532,000. Redmont Wealth Advisors LLC bought a new stake in shares of AstraZeneca in the 4th quarter valued at $122,000. Elyxium Wealth LLC bought a new stake in shares of AstraZeneca in the 4th quarter valued at $102,000. L & S Advisors Inc bought a new stake in shares of AstraZeneca in the 4th quarter valued at $14,863,000. Finally, Hendley & Co. Inc. bought a new stake in shares of AstraZeneca in the 4th quarter valued at $11,373,000. Institutional investors own 40.87% of the company’s stock.
AstraZeneca Stock Performance
AZNCF opened at $187.10 on Monday. AstraZeneca PLC has a 12 month low of $122.26 and a 12 month high of $195.00. The company has a fifty day simple moving average of $187.10 and a 200 day simple moving average of $184.67.
AstraZeneca Company Profile
AstraZeneca (OTCMKTS:AZNCF) is a global biopharmaceutical company that focuses on the discovery, development, manufacturing and commercialization of prescription medicines. The company’s research and development efforts are concentrated in three main therapeutic areas: oncology; cardiovascular, renal and metabolism; and respiratory, inflammation and autoimmunity. AstraZeneca’s product portfolio includes targeted therapies for lung and breast cancers, novel agents for heart failure and chronic kidney disease, and inhaled treatments for asthma and chronic obstructive pulmonary disease.
The company was formed in 1999 through the merger of Sweden’s Astra AB and the United Kingdom’s Zeneca Group, creating one of the world’s largest pharmaceutical firms.
Featured Articles
- Five stocks we like better than AstraZeneca
- The Smart Glasses Gold Rush Is Leaving Old-School Eyewear Behind
- 3 Rare Earth Stocks That Win No Matter What China Does Next
- Amylyx Stock: Why the Full Pipeline Story Matters
- Palantir and Dell Build an AI OS for the Paranoid
Want to see what other hedge funds are holding AZNCF? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (OTCMKTS:AZNCF – Free Report).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.
